CVM Stock Overview
A clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
CEL-SCI Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.42 |
| 52 Week High | US$2.50 |
| 52 Week Low | US$0.33 |
| Beta | 0.69 |
| 1 Month Change | 3.58% |
| 3 Month Change | -26.12% |
| 1 Year Change | -82.18% |
| 3 Year Change | -92.15% |
| 5 Year Change | -97.47% |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| CVM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.1% | 0.4% | 1.5% |
| 1Y | -82.2% | -2.7% | 22.4% |
Return vs Industry: CVM underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: CVM underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| CVM volatility | |
|---|---|
| CVM Average Weekly Movement | 20.4% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CVM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CVM's weekly volatility has increased from 13% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | n/a | Geert Kersten | cel-sci.com |
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis.
CEL-SCI Corporation Fundamentals Summary
| CVM fundamental statistics | |
|---|---|
| Market cap | US$30.90m |
| Earnings (TTM) | -US$27.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs CVM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$18.16m |
| Gross Profit | -US$18.16m |
| Other Expenses | US$9.78m |
| Earnings | -US$27.94m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CVM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 12:10 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CEL-SCI Corporation is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Fein | Chardan Capital Markets, LLC |
| Christian Orquera | First Berlin Equity Research GmbH |
| Vernon Bernardino | H.C. Wainwright & Co. |